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ABSTRACT
Gut microbiome manipulation to alter the gut-lung axis may potentially protect humans against 
respiratory infections, and clinical trials of probiotics show promise in this regard in healthy adults 
and children. However, comparable studies are lacking in overweight/obese people, who have 
increased risks in particular of viral upper respiratory tract infections (URTI). This Addendum further 
analyses our recent placebo-controlled trial of probiotics in overweight/obese people (focused 
initially on weight loss) to investigate the impact of probiotics upon the occurrence of URTI 
symptoms. As well as undergoing loss of weight and improvement in certain metabolic parameters, 
study participants taking probiotics experienced a 27% reduction in URTI symptoms versus control, 
with those ≥45 years or BMI ≥30 kg/m2 experiencing greater reductions. This symptom reduction is 
apparent within 2 weeks of probiotic use. Gut microbiome diversity remained stable throughout 
the study in probiotic-treated participants. Our data provide support for further trials to assess the 
potential role of probiotics in preventing viral URTI (and possibly also COVID-19), particularly in 
overweight/obese people.
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1. Introduction:
The global burden of disease caused by respiratory 
tract infections is substantial, representing 
a significant proportion of physician visits, working 
days lost through sickness, and healthcare 
expenditure.1,2 Recent large epidemiological stu-
dies have observed that being overweight or obese 
appears to be an independent risk factor that 
increases an individual’s risk of both upper and 
lower respiratory tract infections.3–5 Comparable 
findings from the COVID-19 pandemic have 
shown obese patients having both a high risk of 
contracting COVID-19 infection, as well as devel-
oping more severe disease, including increased 
mortality.6 Whilst lifestyle intervention and 
bariatric surgery are major current medical options 
to achieve weight loss and therefore mitigate this 
risk, any potential additional preventative 
approaches would evidently be of keen clinical 
interest.
It is well established that a key function of the 
microbiota of different mucosal surfaces found in 
mammals is in colonization resistance, i.e., the 
prevention of infections either through the direct 
action of microbiota components upon pathogens 
or via a number of indirect routes (primarily 
through interactions with the host immune 
system7). However, a more recent concept has 
been the recognition of specific interactions and 
crosstalk between the gut microbiota and the 
lungs, particularly with regards to respiratory 
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immune and anti-infective responses. This is often 
described as the ‘gut-lung axis,8ʹ and sometimes 
referred to as a common mucosal immunological 
system.9 While the mechanisms underpinning the 
link between obesity and risk of respiratory infec-
tions including COVID-19 are incompletely 
understood, one hypothesis is that obesity-related 
changes in the gut microbiome composition result 
in increased intestinal permeability, endotoxemia, 
and activation of pro-inflammatory host immune 
responses that increase susceptibility to infection 
across all mucosal surfaces.10 Compared to this, 
the recognized association between older age and 
increased risk of URTI may be at least partly 
explained by the shifts in microbiome composi-
tion observed with aging, and associated changes 
in immune response to infective insults.11
By extension, modulation of the gut microbiota 
as a means of influencing the gut-lung axis has been 
an area of active investigation, with probiotics 
being one of the main interventions that has been 
explored in human trials. A number of different 
studies have explored the use of probiotics to 
reduce the risk of respiratory infections, with 
a focus on viral upper respiratory tract infections 
(URTI) in particular (90% of URTIs are viral in 
nature12). To date, several systematic reviews and 
meta-analyses have concluded that probiotics 
appear to have a positive effect in this regard.13–15 
However, these systematic reviews have also noted 
that individual published studies to date are often 
small, with low-quality data and high risk of het-
erogeneity, limiting the applicability of their find-
ings to a general population.13–15 Furthermore, the 
majority of these studies have included only healthy 
children or adults as study participants, with very 
little focus on groups at elevated risk of viral URTIs, 
such as overweight and obese adults.
We hypothesized that probiotic use would 
reduce the risk of symptoms related to URTI in 
an overweight and obese population, and that this 
reduction may be related to gut microbiota- 
mediated mechanisms. In this Addendum, we pre-
sent our additional analysis of a recent double- 
blind placebo-controlled trial we undertook in an 
overweight and obese population where probiotics 
were the intervention, and where the primary end-
point was related to weight loss and lipid 
metabolism.
2. Further analysis of the PROMAGEN study
Our trial examined the impact of probiotics on 
a healthy, free-living, overweight and obese adult 
population (PROMAGEN, ISRCTN12562026).16 
Specifically, this was a double-blind, single-center, 
placebo-controlled trial that recruited 220 people 
with BMI 25–34.9 kg/m2 (30–65 years of age), with 
participants randomized to receive either the Lab4P 
probiotic (50 billion colony-forming units) or 
a matched placebo daily for 6 months. Lab4P com-
prised Lactobacillus acidophilus CUL60 (NCIMB 
30157), Lactobacillus acidophilus CUL21 (NCIMB 
30156), Lactobacillus plantarum CUL66 (NCIMB 
30280) Bifidobacterium bifidum CUL20 (NCIMB 
30153) and Bifidobacterium animalis subsp. lactis 
CUL34 (NCIMB 30172). At the end of the study, 
significant between group decreases were identified 
in body weight (1.3 kg, p < .0001), BMI (0.045 kg/ 
m2, p < .0001), waist circumference (0.94 cm, p  
< .0001), and waist-to-height ratio (0.006, p  
< .0001), all favoring the probiotic arm. 
Improvements in small dense LDL-cholesterol, 
self-perceived quality of life, and the incidence of 
particular symptoms that may be consistent with 
URTI were also observed in the probiotic arm rela-
tive to participants receiving placebo.16 No signifi-
cant adverse events were observed in association 
with probiotic use.
Study participants also contemporaneously 
recorded daily symptom diaries during the trial, 
containing 25 elements related to different organ 
systems and general health. To explore the poten-
tial impact of probiotic use upon URTI symptoms 
in more detail, we further reviewed frequencies of 
those symptoms recorded in symptom diaries that 
could be considered most consistent with URTI. 
The study was performed over the 6 months from 
July to January, and as such included a significant 
period of the conventional peak season for influ-
enza-like illnesses. We selected five key sympto-
matic indicators of URTI that had been recorded, 
all of which have been previously included in vali-
dated symptom scoring systems for viral respira-
tory illness/URTI, namely: cough, sore throat, 
headache, muscle ache and wheeze17,18 (‘URTI 
symptoms’). Further details of the analysis of symp-
tom incidence rate are provided in the 
Supplementary Methods. On review of self- 
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reported URTI symptoms during the study, we 
observed a significant 27% between-group differ-
ence in overall incidence favoring the Lab4P group 
(Incidence Rate Ratio (IRR): 0.73, 95% confidence 
intervals (CI): 0.63, 0.84, p< .0001 (Figure 1)).
Given the data outlined above regarding age and 
obesity as risk factors for URTI, we looked at how 
these factors were related to the recorded URTI 
symptoms in the PROMAGEN cohort. We ana-
lyzed them using a Poisson regression model 
(Figure 1), which identified significant interactions 
with symptom incidence between treatment and 
age (p= .0071) and BMI (p= .0393, Figure 1). 
Stratification of the cohort highlighted the greater 
probiotic impact on incidence rates of URTI symp-
toms in participants ≥45 years old compared to 
younger participants (IRR: 0.60, p< .0001 vs IRR: 
0.90, p= .3336), and in obese participants compared 
to those overweight alone (IRR: 0.57, p< .0001 vs 
IRR: 0.78, p= .0059). Further analysis of additional 
recorded symptoms of potential relevance to URTIs 
(but not included as one of our central five symp-
toms, e.g., sneezing) demonstrated that these 
occurred at either similar or reduced rates in parti-
cipants taking probiotics compared to those taking 
placebo; a pattern was once again observed regard-
ing benefits being generally more prominent in 
participants ≥45 years of age and with BMI 
≥30 kg/m2 (Supplementary Figure S1).
We further explored the dynamics of onset of 
URTI symptoms. On the first day of the study, 
participants in both arms of the PROMAGEN 
study were virtually symptom-free, with only one 
participant in the ≥45 years old placebo group 
reporting cough. After 1 to 2 weeks supplementa-
tion, there was the clear indication of a divergence 
between groups in the time taken to record the first 
symptom favoring the probiotic in the two sub-
groups, namely those ≥45 years old (Figure 2b) 
and the obese (Figure 2d), suggestive of a rapid 
impact of the probiotic upon URTI symptoms. 
These delays in symptom onset were maintained 
over the duration of the study in both the older and 
obese subgroups, and reached significance in the 
case of the participants ≥45 years old (χ2 = 5.436, 
p= .0194, Figure 2d). Collectively, these findings 
lead us to conclude that Lab4P can act rapidly, 
particularly in the ’at-risk’ groups of older and 
obese participants.
Additionally, we investigated the associations 
between the reported URTI symptoms and the gut 
microbiota profiles of participants ≥45 years old in 
the study, to particularly explore whether potential 
URTIs may impact upon gut microbiota composi-
tion (Figure 3 and Supplementary Methods). 
Analysis was performed of 16S rRNA gene sequen-
cing of stool samples from study participants 
≥45 years old who had given stool samples both at 
the beginning and end of the study, as previously 
described.19 For placebo-treated participants, 
a negative correlation was observed between length 
of time with URTI symptoms and stool microbiota 
diversity (as measured by Shannon/alpha diversity 
index; r2 = −0.637, p< .05). In contrast, the Shannon 
Subgroup n IRR (95% CI) p value
p value for 
interaction
All participants 110/110 0.73 (0.63,0.84) <0.0001
Age (years) 0.0071
<45 46/44 0.90 (0.72,1.12) 0.3336
≥45 64/66 0.60 (0.50,0.72) <0.0001
BMI (kg/m2) 0.0393
<30 71/78 0.78 (0.66,0.93) 0.0059
≥30 39/32 0.57 (0.44,0.73) <0.0001
0.4 0.5 0.6 0.7 0.8 0.9 1 1.1 1.2 1.3 1.4 1.5 1.6
Incidence rate ratio (95% CI) 
Favours probiotic     Favours placebo
Figure 1. Overall and subgroup analysis of the impact of probiotic supplementation on the incidence of URTI symptoms. 
Statistical analysis was performed using a generalized linear model with Poisson distribution and log link function, data is presented as 
IRR ± 95% CI (n, number of participants (placebo group/probotic group); IRR, incidence rate ratio; CI, confidence interval).
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diversity of the probiotic group was unaltered by 
the length of exposure of URTI symptoms (r2= 
−0.87, p= .473). Of note, only one included probio-
tic-treated participant had used antibiotics within 3 
weeks of the end of the study stool sample (with 
antibiotics administered for a suspected respiratory 
tract infection); none of the included placebo- 
treated participants had used antibiotics within 
approximately 4 months of the end of the study. 
Together, these data lead us to suggest that in 
participants in the study with URTI symptoms, 
probiotic use may have minimized post-infective 
changes in gut microbiome composition.
3. Discussion:
There is growing evidence supporting the concept 
that gut commensal bacteria (including those com-
monly included in probiotics) are able to suppress 
viruses that enter the host via the upper respiratory 
tract from causing infection, with research to date 
focusing particularly upon influenza. Mechanisms 
by which such bacteria suppress influenza directly 
include absorptive trapping,20 as well as by the 
production of lipopolysaccharide that binds to 
and destabilizes the viral structure.21 One potential 
route by which probiotic bacteria may translocate 
from the gut to the lung (and undertake direct 
protective functions such as absorptive trapping) 
is described by the ‘gut-lymph hypothesis’, i.e. gut 
bacteria within draining chyle from the lower gas-
trointestinal tract entering the lymphatic system 
and subsequently the thoracic duct, before traveling 
directly on to the capillary blood vessels of the 
lungs.22
There are also indirect routes by which the gut 
microbiota prevents influenza infection, including 
an influence upon interferon responses in lung 
stromal cells,23 as well as promotion of antigen 
presenting cell migration and Toll-like receptor- 
mediated T cell antiviral responses.24 Additionally, 
research into the gut-lung axis in COVID-19 
infected patients has shown an altered stool micro-
biome composition compared to controls.25,26 In 
hospitalized patients with COVID-19, stool levels 
of a number of gut commensal bacteria (including 
Bacteroides dorei and Bacteroides ovatus) were 
found to correlate inversely with SARS-CoV-2 
viral load;25 this is of interest, given that such bac-
teria may downregulate expression in the mouse 
gut of angiotensin-converting enzyme 2 (ACE2), 
the receptor used by SARS-CoV-2 to gain entry to 
the host.27 Of particular potential relevance given 
the data presented in our work here, a further 
study – longitudinally analyzing the gut micro-
biome of 100 patients with COVID-19 infection – 
noted consistent underrepresentation of 
Bifidobacteria in patient stool samples throughout 
the course of disease.26
Furthermore, there is now increased under-
standing of the mechanisms by which probiotic 
supplementation of the gut microbiota may directly 
modulate host immunity in this context, predomi-
nantly deriving from mouse models of influenza in 
which Bifidobacteria or Lactobacillus supplementa-
tion resulted in reduced severity of infection.28 
There is evidence from such models that 
Lactobacillus supplementation enhances type 1 
interferon responses29 and increases TNF-α pro-
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Figure 2. Impact of probiotic supplementation on time to 
onset of URTI symptoms during the PROMAGEN study. 
Kaplan-meier plots of time to first URTI symptoms in subgroups 
of participants who were: A) <45 year olds; B) ≥45 year olds; C) 
overweight (BMI <30 kg/m2) and; D) obese (BMI ≥30 kg/m2). 
Statistical analysis was performed using the log-rank Mantel-Cox 
test.
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respiratory viral infection.30 Short-chain fatty acids 
(SCFAs) – the product of fermentation of non- 
digestible carbohydrate and amino acids by gut 
bacteria – appear to be a key group of metabolites 
linking the gut microbiome to these altered 
immune responses.31 Human trials investigating 
probiotics for the prevention of viral respiratory 
infections have shown probiotic-related increases 
in serum interferon-γ32 and Th1 cell activation, 
increased numbers of T helper cells, T killer cells 
and monocytes,33 as well as changes in NK cell 
activity.34
As discussed above, studies to date evaluating the 
role of probiotics for the prevention of viral URTI 
have predominantly focused on healthy adults and 
children and have tended not to explore outcomes 
for the overweight and obese population, or older 
people. There is now recognition of a need for more 
focused studies within this context, including eva-
luation of whether probiotics may alter the impact 
of COVID-19 infection.35 Of note, one early study 
of probiotic supplementation to 28 hospitalized 
patients already diagnosed with COVID-19 
observed eightfold lower rates of respiratory failure 
in patients receiving probiotics compared to 42 
comparator patients receiving medical therapy 
alone;36 however, there are currently no data avail-
able to our knowledge which demonstrate efficacy 
of probiotics for the prevention of COVID-19 
infection in humans. The particular novelty of our 
findings is the recognition that probiotic supple-
mentation may be associated with an overall reduc-
tion of URTI symptoms by as much as 27%, with 
individuals ≥45 years of age and/or with a BMI 
≥30 kg/m2 deriving the greatest benefit of risk 
reduction. The recognition that perturbed gut bar-
rier function is associated with vulnerability to both 
infection and obesity – and that probiotics may be 
able to improve gut barrier integrity – could be 
a potential mechanistic link that explains our find-
ings in patients with an unfavorable BMI.37 With 
regards to our findings on the particular benefits of 
probiotics in older study participants, it is note-
worthy that lower levels of gut Bifidobacteria have 
been associated with older age, and Lactobacillus 
and Bifidobacteria depletion have also been 































Days with URTI symptoms (per 100 days)
Figure 3. Scatterplot of relationship between change in Shannon diversity index of the stool microbiota versus the number of 
days with URTI symptoms in participants ≥45 years old given probiotics or placebo. Shannon diversity was measured in stool 
samples from study participants ≥45 years old at baseline and at end of the study (six months) using 16S rRNA gene profiling. 
Statistical analysis was performed using Pearson’s correlation analysis. Probiotic arm: n = 18; placebo arm: n= 13.
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observed in the gut microbiota of certain patients 
with respiratory infections, including COVID-19.38
The apparent protective impact of the probiotic 
on gut microbial diversity in study participants who 
developed URTI symptoms is another finding of 
interest. While much of the focus to date in gut- 
lung axis research has been on the impact of the gut 
microbiome on the lung, the bidirectional nature of 
this relationship is now increasingly acknowledged. 
Specifically, changes in gut microbiome composi-
tion and functionality post-viral respiratory tract 
infection that have been observed (even in the 
absence of detectability of the virus within the gas-
trointestinal tract) are associated with changes in 
host immune responses,39 and potentially result in 
increased vulnerability to secondary respiratory 
infections.40 In mouse models of influenza, 
a reduction in gut Lactobacillus has been observed 
after infection,41 while Bifidobacteria (including 
Bifidobacterium animalis) were found to be signifi-
cantly elevated in the gut of surviving mice com-
pared to dead or mock-infected mice.42
The major limitation of our study is using self- 
reported symptoms as a proxy for URTI, without 
any definitive clinical/laboratory data to confirm 
true infection; however, the symptoms that we 
measured show close overlap with those in estab-
lished symptoms scoring systems for predicting 
URTIs/viral respiratory illness.18 There were signif-
icantly fewer of our defined URTI symptoms 
observed in all participants in the first 3 months 
of the study (the ‘summer’ months) compared to 
the last 3 months (‘winter’ months) (p= .0108), 
again supporting the concept that the symptoms 
which we selected represent winter respiratory 
viral illness (Supplementary Figure S2). 
Furthermore, since the reporting of URTI symp-
toms in this study was self-recorded, statistical 
results may be subject to reporting/recall bias. 
However, a number of different approaches to 
symptom recording were taken in order to mitigate 
the possibility of such bias (Supplementary 
Methods 1.1), and the double-blind nature of the 
trial means that this is unlikely to have contributed 
significantly to the between-group differences 
observed. Whilst we have made some speculation 
as to the potential applicability of our data to 
patients with COVID-19 infection, our study was 
performed before the pandemic occurred, and we 
did not have any symptom data relating to other 
potentially important indicators of particular cor-
onavirus infections including COVID-19, such as 
loss of taste/smell. An additional limitation is that 
our definition of cough covered any aspect of 
coughing occurring during the course of the 
study, and this also may not align with more spe-
cific features of URTI (e.g., cough with coryza). 
Nevertheless, it is clearly of interest that in the 
PROMAGEN study, even the incidence of cough 
alone was reduced by ~33% (0.38 per 100 person 
days in probiotic arm, 0.57 per 100 person days in 
placebo arm; IRR: 0.67, CI: 0.50, 0.90, p= .0073) in 
participants receiving probiotics compared to those 
receiving placebo.16 As such, one potential area for 
future exploration may be the potential impact of 
probiotics upon other human diseases for which 
cough is a predominant feature, including allergic 
diseases such as asthma; administration of 
a Lactobacillus rhamnosus resulted in lung protec-
tion in a murine allergic respiratory disease model, 
with the probiotic demonstrated to alter respiratory 
IL-1β levels, as well as airway total cell counts and 
lymphocyte counts.43
4. Conclusions:
In conclusion, our results extend upon existing data 
regarding the impact of probiotics upon viral 
URTI, by suggesting that probiotics may have 
a potential use for reducing URTI symptoms in 
overweight and obese people, and especially those 
of older age. Furthermore, the Lab4P probiotic 
consortium may also have a potential role in stabi-
lizing/preventing changes in gut microbiome com-
position in response to an URTI. Probiotics are 
considered overall safe and well tolerated, and rela-
tively limited alternative therapeutic options cur-
rently exist for prevention of URTIs (including 
COVID-19); as such, we feel that a compelling 
case exists for further randomized studies to pro-
spectively explore the potential impact of probiotics 
on prevention of respiratory infection in particular 
for those at higher risk, including obese and older 
people. Furthermore, there is a need for additional 
research to better delineate mechanisms by which 
probiotic bacteria – either directly or via immune 
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modulation – impact upon the gut-lung axis.
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